The verdict
Our read at a glance.
Whether gonadorelin is understood as the native GnRH hormone whose effect depends entirely on how it is given (pulses stimulate, continuous suppresses), with approved diagnostic and pulsatile-fertility uses, rather than a proven alternative to hCG for maintaining testosterone on testosterone therapy.
- The signal
- As the native hormone, gonadorelin reliably triggers an LH and FSH rise when given, which is the basis of its diagnostic pituitary test, and delivered in pulses by pump it can restore ovulation in women whose problem is a missing hypothalamic signal. Its branded products are now largely discontinued in the US. Its popular off-label use, replacing hCG to keep the testicular axis active during testosterone therapy, rests mostly on physiology and anecdote rather than good trials, and is limited by how briefly it acts.
- The unknown
- Whether intermittent gonadorelin injections without a pump can meaningfully preserve testosterone production and fertility in men on testosterone, the use it is most marketed for, is essentially untested against hCG, and its very short half-life makes durable stimulation doubtful.
- Our read
- The body's own fertility switch, and a lesson in timing. Gonadorelin is native GnRH: in pulses it turns the reproductive axis on (its diagnostic and pump-based fertility uses), while the long-acting agonist versions turn it off. Sold now mostly as a compounded, off-label alternative to hCG for men on testosterone, it is limited by a very short half-life and thin evidence for that use. Read it as an established hormone with narrow approved roles, not a proven testosterone-preserving peptide.
The mechanism
How it works.
The hypothalamus runs the reproductive system by releasing GnRH (gonadotropin-releasing hormone) in brief pulses; each pulse tells the pituitary to release LH and FSH, which drive the ovaries or testes. Gonadorelin is synthetic GnRH, the exact same ten-amino-acid hormone. Given in pulses that copy the natural rhythm with a pump, it switches the axis on, which is how it induces ovulation in women missing the hypothalamic signal and how its diagnostic test works. The twist is that the receptor only responds to a pulsing signal: flood it with a constant, long-acting version (the GnRH agonist drugs) and after a brief surge it shuts down, which is why those drugs are used to suppress hormones in prostate cancer or endometriosis. Gonadorelin itself acts only briefly, breaking down within minutes, which is both why pulsatile therapy needs a pump and why its popular use as a steady hCG substitute is pharmacologically shaky.
Safety & regulatory boundary
The consequential part.
Gonadorelin is generally well tolerated, with headache, nausea, and injection-site reactions, and rare allergic reactions with repeated dosing; in fertility use, pulsatile therapy carries a risk of multiple pregnancy. Its approved roles are a diagnostic test of pituitary function and pulsatile, pump-delivered ovulation induction in hypothalamic amenorrhea; branded US products are largely discontinued, so most current supply is compounded. Using gonadorelin as an off-label substitute for hCG during testosterone therapy is common in men's-health clinics but is not well studied and is limited by the drug's very short action. It is the native hormone, the opposite-acting counterpart to the long-acting GnRH agonists such as leuprolide and goserelin that shut the axis down.
What's next
What we're watching.
Trials of intermittent, non-pump gonadorelin for preserving fertility and testosterone in men on testosterone, head-to-head against hCG, and the practical impact of branded products being discontinued.
Context
Why this is discussed.
Gonadorelin is the body's own master fertility signal, and it shows one of the most surprising rules in hormone biology: given in natural pulses it switches the reproductive axis on, but given steadily, as the long-acting agonist drugs, it switches it off. It is also sold by compounding pharmacies as a natural alternative to hCG for men on testosterone, which is where the hype outruns the evidence.
The evidence base
8 cited references.
Registered trials1
ClinicalTrials.gov · COMPLETED · 2012-04-25
Indexed literature (PubMed)7
Fanis P et al. · Int J Mol Sci · 2023
Marshall JC et al. · Mol Cell Endocrinol · 2001
Tarlatzis BC et al. · Best Pract Res Clin Obstet Gynaecol · 2007
Filicori M et al. · Fertil Steril · 2018
Messinis IE · Hum Reprod · 2005
Everaere H et al. · Fertil Steril · 2025
Shalev E et al. · J Obstet Gynaecol Can · 2003
Keep reading